Search Results - "Strasser, Simone I."

Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study (OPERA‐C).

Authors: Clark, Paul J. Valery, Patricia C. Strasser, Simone I. et al.

Source: Drug & Alcohol Review. Sep2024, Vol. 43 Issue 6, p1559-1572.

Initial Trans-Arterial Chemo-Embolisation (TACE) Is Associated with Similar Survival Outcomes as Compared to Upfront Percutaneous Ablation Allowing for Follow-Up Treatment in Those with Single Hepatocellular Carcinoma (HCC) ≤ 3 cm: Results of a Real-World Propensity-Matched Multi-Centre Australian Cohort Study

Authors: Abdelmalak, Jonathan Strasser, Simone I. Ngu, Natalie L. et al.

Source: Cancers. Sep2024, Vol. 16 Issue 17, p3010. 31p.

Different Patterns of Care and Survival Outcomes in Transplant-Centre Managed Patients with Early-Stage HCC: Real-World Data from an Australian Multi-Centre Cohort Study.

Authors: Abdelmalak, Jonathan Strasser, Simone I. Ngu, Natalie L. et al.

Source: Cancers. Jun2024, Vol. 16 Issue 11, p1966. 30p.

Improved Survival Outcomes with Surgical Resection Compared to Ablative Therapy in Early-Stage HCC: A Large, Real-World, Propensity-Matched, Multi-Centre, Australian Cohort Study.

Authors: Abdelmalak, Jonathan Strasser, Simone I. Ngu, Natalie et al.

Source: Cancers. Dec2023, Vol. 15 Issue 24, p5741. 27p.

Surviving Hepatitis C—Understanding Death and Survival Beyond Cure.

Authors: Clark, Paul J. Valery, Patricia C. Strasser, Simone I. et al.

Source: Alimentary Pharmacology & Therapeutics. Sep2025, Vol. 62 Issue 6, p602-619. 18p.

Expansion of Liver Transplantation Criteria for Hepatocellular Carcinoma from Milan to UCSF in Australia and New Zealand and Justification for Metroticket 2.0.

Authors: Barreto, Savio G. Strasser, Simone I. McCaughan, Geoffrey W. et al.

Source: Cancers. Jun2022, Vol. 14 Issue 11, p2777-2777. 14p.

Hepatitis C Virus Antiviral Drug Resistance and Salvage Therapy Outcomes Across Australia.

Authors: Wang, Dao Sen Phu, Amy McKee, Kristen et al.

Source: Open Forum Infectious Diseases. Apr2024, Vol. 11 Issue 4, p1-9. 9p.

The IC3 trial: protocol for a multicentre individually randomised controlled trial to compare a cirrhosis detection and hepatocellular carcinoma surveillance pathway vs usual care in Australian general practice for 45–75 years old with risk factors for chronic liver disease

Authors: Adams, Leon A. de Guingand, Deborah Jeffrey, Gary P. et al.

Source: Trials. 9/24/2025, Vol. 26 Issue 1, p1-18. 18p.

A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (SOCRATES HCC).

Authors: Wigg, Alan Tibballs, Jonathan Woodman, Richard et al.

Source: BMC Cancer. 7/8/2024, p1-9. 9p.

Implementing palliative care in hepatocellular carcinoma ambulatory clinics—study protocol for Accelerated translational research in PRImary liver CAncer (APRICA) randomised controlled palliative care trial.

Authors: Gofton, Cameron Di Bartolomeo, Anna Boutros, Rose et al.

Source: Trials. 11/6/2024, Vol. 25 Issue 1, p1-10. 10p.

High end‐of‐treatment hepatitis B core‐related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy.

Authors: Hume, Simon J. Wong, Danny K. Yuen, Man‐Fung et al.

Source: Liver International. Oct2024, Vol. 44 Issue 10, p2605-2614. 10p.

Editorial: tailoring mycophenolate mofetil rescue therapy for success in autoimmune hepatitis—authors' reply.

Authors: Nicoll, Amanda J. Roberts, Stuart K. Strasser, Simone I.

Source: Alimentary Pharmacology & Therapeutics. Jun2019, Vol. 49 Issue 11, p1450-1451. 2p.

Letter: elderly AIH patients—an important subgroup. Authors' reply.

Authors: Nicoll, Amanda J Roberts, Stuart K. Mitchell, Joanne et al.

Source: Alimentary Pharmacology & Therapeutics. Sep2019, Vol. 50 Issue 5, p615-615. 1p.

National Survey of Real‐World Australian Treatment Patterns for Patients With Very‐Early‐To Intermediate‐Stage Hepatocellular Carcinoma.

Authors: Roberts, Stuart K. Majeed, Ammar Rasaratnam, Kiran et al.

Source: Cancer Medicine. Mar2025, Vol. 14 Issue 5, p1-11. 11p.

Drug‐induced liver injury from selective androgen receptor modulators, anabolic‐androgenic steroids and bodybuilding supplements in Australia.

Authors: Nash, Emily Nicoll, Amanda Batt, Nicholas et al.

Source: Alimentary Pharmacology & Therapeutics. Apr2024, Vol. 59 Issue 8, p953-961. 9p.

Impact of Share 35 liver transplantation allocation in Australia and New Zealand.

Authors: Fink, Michael A. Gow, Paul J. McCaughan, Geoffrey W. et al.

Source: Clinical Transplantation. Jan2024, Vol. 38 Issue 1, p1-10. 10p.

Low rate of surgical site infections after liver transplantation: A 5‐year retrospective cohort study.

Authors: Tun, Taryar Marinelli, Tina Liu, Ken et al.

Source: Transplant Infectious Disease. Aug2024, Vol. 26 Issue 4, p1-7. 7p.

Stopping nucleot(s)ide analogues in non‐cirrhotic HBeAg‐negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels.

Authors: Hall, Samuel A. L. Burns, Gareth S. Anagnostou, Despina et al.

Source: Alimentary Pharmacology & Therapeutics. Jul2022, Vol. 56 Issue 2, p310-320. 11p. 2 Charts, 3 Graphs.

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study.

Authors: Ruane, Peter Strasser, Simone I. Gane, Edward J. et al.

Source: Journal of Viral Hepatitis. Jun2019, Vol. 26 Issue 6, p770-773. 4p.

Is it safe to expand the indications for split liver transplantation in adults? A single‐center analysis of 155 in‐situ splits.

Authors: Lau, Ngee‐Soon Ly, Mark Liu, Ken et al.

Source: Clinical Transplantation. Jul2022, Vol. 36 Issue 7, p1-9. 9p.